NeuroSense Therapeutics (NASDAQ:NRSN) Trading 0.4% Higher – What’s Next?

NeuroSense Therapeutics Ltd. (NASDAQ:NRSN)’s share price shot up 0.4% on Monday . The stock traded as high as $0.4990 and last traded at $0.4670. 452,053 shares changed hands during trading, an increase of 52% from the average session volume of 297,059 shares. The stock had previously closed at $0.4652.

Analyst Ratings Changes

Several equities research analysts have recently commented on the company. D. Boral Capital restated a “buy” rating and issued a $14.00 price objective on shares of NeuroSense Therapeutics in a research note on Wednesday, April 8th. Weiss Ratings downgraded NeuroSense Therapeutics from a “sell (d-)” rating to a “sell (e+)” rating in a research report on Thursday. One analyst has rated the stock with a Strong Buy rating, two have given a Buy rating, one has issued a Hold rating and one has issued a Sell rating to the company’s stock. Based on data from MarketBeat, the stock has a consensus rating of “Moderate Buy” and an average target price of $8.50.

NeuroSense Therapeutics Stock Up 0.4%

The firm’s fifty day moving average price is $0.71 and its 200 day moving average price is $0.80. The stock has a market cap of $17.64 million, a PE ratio of -0.86 and a beta of 1.62.

Insiders Place Their Bets

In related news, CFO Or Eisenberg acquired 250,000 shares of the company’s stock in a transaction on Tuesday, June 16th. The stock was acquired at an average price of $0.80 per share, with a total value of $200,000.00. Following the acquisition, the chief financial officer directly owned 1,504,050 shares of the company’s stock, valued at approximately $1,203,240. This trade represents a 19.94% increase in their ownership of the stock. The purchase was disclosed in a filing with the SEC, which is available through this link. Also, CEO Alon Ben-Noon acquired 250,000 shares of the business’s stock in a transaction dated Tuesday, June 16th. The shares were purchased at an average price of $0.80 per share, with a total value of $200,000.00. Following the transaction, the chief executive officer owned 4,534,233 shares of the company’s stock, valued at approximately $3,627,386.40. This represents a 5.84% increase in their ownership of the stock. The SEC filing for this purchase provides additional information. Insiders own 27.40% of the company’s stock.

Institutional Investors Weigh In On NeuroSense Therapeutics

Several large investors have recently made changes to their positions in NRSN. Yorkville Advisors Global LP bought a new stake in NeuroSense Therapeutics in the 4th quarter worth approximately $77,000. Squarepoint Ops LLC raised its holdings in shares of NeuroSense Therapeutics by 91.0% during the 3rd quarter. Squarepoint Ops LLC now owns 95,375 shares of the company’s stock worth $119,000 after acquiring an additional 45,450 shares in the last quarter. Jane Street Group LLC bought a new position in shares of NeuroSense Therapeutics during the 2nd quarter valued at approximately $54,000. Finally, Two Sigma Investments LP bought a new position in shares of NeuroSense Therapeutics during the 3rd quarter valued at approximately $26,000. 1.04% of the stock is owned by institutional investors.

About NeuroSense Therapeutics

NeuroSense Therapeutics, Inc is a clinical-stage biopharmaceutical company focused on the discovery and development of novel therapies for neurodegenerative and age-related neurological disorders. The company’s primary mission is to address unmet medical needs in diseases characterized by protein aggregation, chronic inflammation and cellular senescence in the central nervous system.

At the core of NeuroSense’s approach is a proprietary senotherapeutic platform designed to selectively target and clear senescent cells that contribute to neurodegeneration.